Study finds new treatment for spinal muscular atrophy safe for infants

December 06, 2016

Infants as young as five weeks old with the most severe form of spinal muscular atrophy (SMA) - a leading genetic cause of infant mortality - can be treated safely with nusinersen. This investigational treatment slowed progression of the disease, improved survival, and in some cases demonstrated remarkable improvement in muscle function, according to research published online today by The Lancet.

"With nusinersen, these infants are not only living longer, but they're living better," said Richard S. Finkel, MD, lead author of the study and chief of neurology at Nemours Children's Hospital in Orlando, Fla. "SMA is no longer a death sentence for infants. This treatment is by no means a cure, but it is more than we've ever been able to offer these families before."

The multi-site, phase two, open-label trial of patients with infant-onset SMA targeted the SMN2 gene with a tiny fragment of DNA called an anti-sense oligonucleotide (ASO), injected directly into the spinal fluid of 20 participating infants. This ASO gets absorbed into nerve cells of the spinal cord and brain and promotes increased production of a critical protein that is deficient in babies with SMA. Not only was the series of nusinersen treatments delivered safely to these fragile babies, but in the majority of patients it was found to halt progression of the disease and in many cases improve motor function, sometimes enabling children to gain skills not seen in SMA Type 1 - sitting, rolling over, and standing - as well as improving survival without dependence upon the continuous use of a ventilator.

An estimated one in 40 adults is a carrier of SMA, and one of every 11,000 babies are born with this genetic disease. SMA is typed by severity and age of onset. Babies born with SMA Type 1, the most severe form, are not expected to live until their second birthday without feeding and breathing support. SMA occurs from a defect in the gene responsible for producing Survival Motor Neuron (SMN), a protein critical for normal cell function. Nusinersen is designed to increase the production of this protein by modifying a closely ¬related gene to compensate for the genetic defect.

Asher Camp of Lakeland, Fla., now age 3, was diagnosed with SMA Type 1 when he was six months old and began treatment a month later at Nemours Children's Hospital through this clinical trial. He and his family have seen remarkable development that they never thought would be possible when they received his diagnosis in 2013.

"This is a new day, a new era when rare diseases like SMA might just very well be cured in our lifetime. Miracles are happening. Asher's life is a miracle. Thanks to unbelievable funding for research, awareness, and patient advocacy, we can imagine a day when parents are no longer sent home on diagnosis day with a death sentence but rather sent home with hope for the future," said Asher's mother, Amanda Camp. "What if diagnosis day is a day when parents can still imagine their children crawling, walking, running and playing? Imagine the day Asher leaves his wheelchair behind. Imagine."

The study builds on the body of research supporting the effective use of nusinersen, one of the first therapies for SMA, developed by Ionis Pharmaceutical in partnership with Biogen. Biogen has submitted a nusinersen for approval in the U.S. by the Food and Drug Administration and in Europe by the European Medicines Agency. Both the Priority Review and Accelerated Assessment designations can reduce the standard review time. Biogen is also preparing for the potential launch of nusinersen, to be sold as Spinraza, possibly as early as the end of 2016 or the first quarter of 2017.

Dr. Finkel and his team are continuing to build on the safety profile of nusinersen through several ongoing clinical trials at Nemours Children's Hospital. NURTURE is an open-label, ongoing Phase 2 clinical trial in pre-symptomatic infants with SMA who are up to six weeks of age at time of first dose to determine whether treatment before symptoms begin would prevent or delay the onset of SMA symptoms. Additionally, Nemours Children's Hospital is now participating in the Biogen-sponsored expanded access program, to provide nusinersen treatment for patients with SMA Type 1 until the drug is approved by regulatory authorities and is commercially available.
-end-
Finkel, Richard S, et al. "Treatment of Infantile-onset Spinal Muscular Atrophy with Nusinersen: A Phase 2, Open-label, Dose-escalation Study." The Lancet (2016): http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31408-8/fulltext. 6 Dec. 2016. Web.

About Nemours Children's Health System

Nemours Children's Health System is an internationally recognized children's health system that owns and operates the Nemours/Alfred I. duPont Hospital for Children in Wilmington, Del., and Nemours Children's Hospital in Orlando, along with major pediatric specialty clinics in Delaware, Florida, Pennsylvania and New Jersey. Established as The Nemours Foundation through the legacy and philanthropy of Alfred I. duPont, Nemours offers pediatric clinical care, research, education, advocacy, and prevention programs to all families in the communities it serves.

The Reis Group

Related Spinal Muscular Atrophy Articles from Brightsurf:

Atrophy can be combated by boosting expression of an enzyme produced in muscles
Study showed that targeted stimulation of PKA production promoted muscle growth and enhanced resistance to fatigue.

A multicenter look at gene therapy for spinal muscular atrophy
A new study confirms the safety and efficacy of gene therapy in children with spinal muscular atrophy under two years old.

Treat early or wait? Experts ponder best way to manage milder forms of spinal muscular atrophy
The advent of therapeutic interventions for spinal muscular atrophy (SMA) has increased the importance of presymptomatic diagnosis and treatment.

Spinal muscular atrophy (SMA): Newborn screening promises a benefit
The earliest possible diagnosis and treatment of infantile SMA through newborn screening leads to better motor development and less need for permanent ventilation as well as fewer deaths.

Exposure to PM 2.5 pollution linked to brain atrophy, memory decline
Women in their 70s and 80s who were exposed to higher levels of air pollution experienced greater declines in memory and more Alzheimer's-like brain atrophy than their counterparts who breathed cleaner air.

Nusinersen improves motor function in adults with spinal muscular atrophy
A study published in the Journal of Neuromuscular Diseases presents the first evidence of mild improvement or stabilization of motor and respiratory function in adults with spinal muscular atrophy type 3 (SMA3) treated with Nusinersen, which was the case even in patients who have had the disease for 20 years or more.

Transplanting adult spinal cord tissues: A new strategy of repair spinal cord injury
Spinal cord injury repair is one of the most challenging medical problems, and no effective therapeutic methods has been developed.

Memory tests predict brain atrophy and Alzheimer's disease
Use of two episodic memory tests help in predicting brain atrophy and Alzheimer's disease, as indicated by a study carried out at the University of Helsinki and the University of California.

Researchers correlate spinal muscular atrophy disease expression with haplotypes
A natural history study has provided the first comprehensive clinical description of spinal muscular atrophy (SMA) within the Amish and Mennonite communities and correlates ancestral chromosome 5 haplotypes and SMN2 copy number with disease severity.

Spinal muscular atrophy drug may be effective if started later than previously shown
A drug shown to be effective in the treatment of babies with the rare muscle-wasting disease spinal muscular atrophy may be effective for muscle control even when treatment is started in children seven months and older, according to a study published in the Aug.

Read More: Spinal Muscular Atrophy News and Spinal Muscular Atrophy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.